Get the latest Septerna, Inc. (SEPN) stock news and headlines to help you in your trading and investing decisions.

About Septerna Inc. Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discover ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to read my most recent analysis.

We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands ...

--Septerna, Inc., a biotechnology company pioneering a new era of G protein-coupled receptor drug discovery, today highlighted key business updates and upcoming milestones and reported financial ...

Septerna has landed a $200 million deal with Novo Nordisk to develop oral weight-loss and diabetes drugs, with potential for $2 billion more in milestone payments.

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million.

Septerna, Inc. ( (SEPN) ) has released its Q3 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors. Septerna, Inc. is a clinical-stage biotechnology company ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Septerna’s lead program is in Phase 1 testing for hypoparathyroidism. The therapies available and in development for this rare disease are injectable, and Septerna aims to stand apart with an ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.